ArticleJournal of neuro-oncology2025
Long-term tumour control of cystic and solid vestibular schwannoma treated with LINAC-based stereotactic radiosurgery: a retrospective analysis.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Residual tumor volume guides post-surgical treatment paradigm and need for salvage radiotherapy in vestibular schwannoma management.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe implications of intratumoural cystic change on management and treatment outcomes in vestibular schwannoma (VS) remain uncertain. This retrospective analysis aims to compare the treatment outcomes of solid and cystic tumours treated with linear accelerator (LINAC)-based stereotactic radiosurgery (SRS).
methodsSixty-eight patients were analysed including 22 with cystic tumours. All received a marginal dose of 12 Gy to the 80% isodose line (range: 70-90%) delivered in a single fraction. Local progression was defined as a maximum linear dimension (MLD) enlargement of > 2 mm persisting for over 2 years, pseudoprogression as an MLD enlargement of > 2 mm within the first 2 years followed by stability or reduction.
resultsWith an average follow-up of 92.2 months, crude tumour control rates were similar: 95.5% for cystic and 93.5% for solid tumours. Pseudoprogression occurred in 7 patients (10.3%), 2 with solid (4.3%) and 5 with cystic VS (22.7%). The mean MLD reduction was 4.2 mm for solid tumours and 5.0 mm for cystic tumours (p = 0.51). Only pretreatment size correlated with the percentage reduction in tumour diameter (p = 0.025). Although a higher proportion of cystic tumours demonstrated at least a 10%, 20%, and 30% size reduction compared to solid tumours, none of these differences were statistically significant.
conclusionLINAC-based SRS achieves similar tumour control for both cystic and solid VS. Despite cystic tumours being typically of higher Koos grade, they may demonstrate numerically greater reduction after SRS. Future studies should aim to standardise the criteria for classifying cystic tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.